Biotech Company With Clinical Operations Developing Psychedelic Medicine To Treat Addiction

First 3 UK Clinics Opened In 2021, Targeting 20 Clinics By 2024 ~$100M In Revenue

Free
Awakn Life Sciences Corp. Profile

 AWAKN-BANNER-33

 

 

 

 

   

How Big Is The Market?

The private global substance Addiction treatment industry was valued at USD17.5bn per annum in 2019 and is forecast to increase to USD31.5bn per annum by 2027.

 

Alcohol Use Disorder accounts for 30% of the overall treatment market, yet only 16% of people who suffer from AUD seek out treatment and of thsoe few that do, 75% of them will relapse within a year.

 

Prevalence of Addiction?

How Is This Done?

Therapeutics Development Strategy

 

Our research team consists of world leading experts in the fields of drug development, clinical research, psychiatry, psychotherapy and neurochemistry. We have focused our research activities on treating addictions where the consequences for the patient, their family and society are most severe.

 

Clinics 

  • Providing the latest evidence backed therapeutics to treat addiction and mental health.
  • Develop and fine tune the business and delivery model for therapeutics developed in our R&D business. Generate real world data and evidence to support regulatory approval applications.
  • Generate revenue.

 

 

Delivery: Clinics

AWAKN´S PIPELINE

Comparables

 

 Partnerships - Scaling our reach beyond our core territories through licensing and partnerships to enable Addiction treatment practitioners to deliver the Awakn methodology.

 

 

Awakn In The Media

 

Screen-Shot-2021-11-01-at-5-58-38-PM

 

 

 

RECENT PRESS RELEASES

 

 

Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program

 

Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada

Last changed at 07-Nov-2022 09:38AM by AGORACOM